Multiple Myeloma

MRD and ctDNA testing could revolutionize monitoring and diagnosing precursor diseases of multiple myeloma.

High-dose busulfan-melphalan enhances VRd therapy, improving progression-free survival in high-risk multiple myeloma patients undergoing ASCT.

Mount Sinai's study uncovers how ciltacabtagene autoleucel enhances long-term remission in multiple myeloma by leveraging the patient's immune response.

Talquetamab shows promising efficacy in heavily pretreated patients with relapsed/refractory multiple myeloma, reinforcing its role in advanced treatment strategies.

The FDA approves daratumumab and hyaluronidase for high-risk smoldering multiple myeloma, significantly improving patient outcomes and progression-free survival.

CAR-T and BsAb therapies revolutionize multiple myeloma treatment but pose infection risks, necessitating vigilant monitoring and tailored prevention strategies.

RSV infections in multiple myeloma patients delay treatment but do not increase mortality, highlighting the need for further research on infection management.

Research reveals a notable risk of invasive fungal infections in multiple myeloma patients undergoing BCMA-targeted CAR T-cell therapy, highlighting the need for vigilant monitoring.

Expert shares notable findings presented at the 2025 IMS Annual Meeting.

FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma, enhancing treatment options and survival rates for patients with limited therapies.

The move emphasizes the need for vigilant monitoring.

Frail patients with multiple myeloma (MM) can safely reduce dexamethasone use, enhancing treatment outcomes without increasing infection risks.

In this video, experts who attended the 2025 International Myeloma Society (IMS) Annual Meeting highlighted topics of interest as well as pivotal data.

Alice Wang, PharmD, BCOP, discusses the rapid infusion of isatuximab for multiple myeloma, highlighting its benefits, safety, and improved patient convenience in treatment.

In a dose-escalation portion of LINKER-MM4, linvoseltamab monotherapy demonstrated a high overall response rate (ORR) and minimal residual disease (MRD) negativity in both transplant-eligible and transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM).

New research links rapid CAR T-cell expansion to delayed neurotoxicity in patients with multiple myeloma.

Elranatamab enhances MRD negativity in relapsed/refractory multiple myeloma post idecabtagene vicleucel, promising improved treatment outcomes.

Belantamab mafodotin with bortezomib shows promising survival benefits for lenalidomide-refractory multiple myeloma patients.

Intravenous immunoglobulin (IVIG) treatment significantly reduces infection rates in multiple myeloma patients receiving BCMA bispecific antibodies, showcasing its clinical benefits.

Outpatient use of bispecifics and CAR T-cell therapies in multiple myeloma can expand access.

Teclistamab shows promising results in frontline multiple myeloma treatment, achieving high MRD negativity rates, but safety concerns remain.

Elranatamab combined with daratumumab and lenalidomide shows promising results for treating newly diagnosed multiple myeloma, enhancing patient outcomes.

An expert discusses the benefits of anti-CD38 quadruplet regimens for elderly multiple myeloma patients.